MATERIALS AND METHODS

Human MK and antibodies
To generate human MK protein, an expression vector for yeast (Pichia pastoris GS115; Research Corporation Technologies) was constructed by inserting a cDNA fragment covering the open reading frame of human MK into pHIL-D4 (In Vitrogen). Following transfection of the expression vector into yeast, selection with histidine and G418 was carried out. The human MK protein was purified from yeast by anion exchange chromatography and affinity chromatography on a heparin column. The purified protein exhibited neurotrophic activity comparable with that of L cell-produced mouse MK .
Rabbit and chicken antibodies were raised against the yeastproduced human MK, and were precipitated with ammonium sulphate, and affinity purified with a human MK-column. These antibodies specifically detected human MK on Western blotting analysis (data not shown). Peroxidase labelling of the antibodies was carried out as described (Ishikawa et al, 1993) .
Serum samples
Sera were obtained from blood collected from normal individuals (n = 135; male = 94; female = 41; ages 20-29 = 31; 30-39 = 59; 40-49 = 25; 50-59 = 11 ; > 60 = 9; median value = 34; average value = 37.6), cancer patients (n = 150; male = 96; female = 54; ages 26-85; median value = 64; average value = 62.9) (Table 1 ) and other patients with or without inflammation (n = 80; male = 35; female = Serum midkine levels are increased in patients with various types of carcinomas 45; ages 20-70), and were immediately frozen and kept at -20°C until assay. We regard those with C-reactive protein (CRP) values > 0.1 mg ml -1 as those with inflammation and those with CRP values < 0.1 mg ml -1 as those without inflammation. Except otherwise specified, sera from cancer patients were obtained before surgical or other treatment. Informed consent was obtained from patients and normal individuals according to the guidelines approved by Ethical Committee of the University Hospitals. Stage of carcinoma was determined by the TNM classification. C-reactive protein level was determined by latex aggregation method.
Enzyme-linked immunoassay (EIA) for human MK
As a standard method, 50 µl of rabbit anti-human MK antibodies at a concentration of 5.5 µg ml -1 in phosphate-buffered saline (PBS) was adsorbed onto the wells of microtiter plates (Polysorp plates, Nunc) for 16 h at room temperature. After washing with 1% Tween 20 in PBS, the wells were blocked with 150 µl of 0.5% BSA in PBS for 2 h at 37°C. On the other hand, control human MK samples or serum samples (10 µl each) were mixed with 100 µl of 50 mM Tris HCl (pH 8.4), 0.5 M KCl, 0.5% bovine serum albumin (BSA), 0.01% Microcide I (aMReSCO, Solon, Ohio, USA) containing peroxidase-labelled chicken anti-human MK antibodies (0.1 µg ml -1 ). Aliquots of 50 µl of this mixture were added into the wells of microtiter plates prepared as described above. After incubation for 1 h at room temperature, the wells were washed five times with 1% Tween 20 in PBS. Aliquots of 100 µl of a substrate solution (tetramethylbenzidine at 0.5 mg ml -1 in Dako S1600, Dako, USA) were added into the wells and the plates were incubated for 30 min at room temperature. The reaction was stopped by adding 100 µl of 2 N sulphuric acid, and OD450 was detected using a multiplate reader (Model 3550, BioRad).
Statistics
Statistical significance was evaluated by Mann-Whitney U test. Correlation was examined by Spearman's correlation coefficient by rank with Z conversion of Fisher's r.
RESULTS
EIA for MK employing two polyclonal antibodies from different species
The newly developed EIA for human MK employed a combination of two anti-human MK antibodies from different species (rabbit and chicken). This procedure increased the sensitivity of the detection of human MK, as compared with the use of rabbit antibodies alone ( Figure 1A) . No cross-reactivity was observed with human pleiotrophin, which shows 45% sequence identity to human MK ( Figure 1B ).
Serum MK levels of normal controls and cancer patients
Using this EIA, we determined serum MK levels of 135 control individuals. Normal serum MK level was 0.154 ± 0.076 ng ml -1 (mean ± SD), and in no case did the value reach 0.5 ng ml -1 (Figure 2 ). Thus 0.5 ng ml -1 was set as the cut-off value. There were no significant differences in MK values between men and women, or among age groups: As an example, in the normal control with ages > 50 (n = 20, average age = 60), the MK value was 0.184 ± 0.111 ng ml -1 . Serum MK levels of 150 cancer patients showed a profile significantly different from that of normal controls (P < 0.001, Mann-Whitney U test) (Figure 3) .
Eighty-seven percent of the patients had a value higher than 0.5 ng ml -1 . As shown in Figure 3 , the increase in serum MK level was observed in all ten types of carcinomas examined. In addition, each tissue type showed a similar profile of serum MK level, suggesting that the profile of increased serum MK level was general rather than tissue-specific.
In case of gastric carcinomas and lung carcinomas, sera from patients with carcinomas at early stages were available in large numbers to test whether serum MK level was increased at the early stages. We found that statistically significant increase in MK level was observed even at stage I of these carcinomas (Table 2) . Although the average value of serum MK was lower in stage I than in stages II-IV, the differences were not statistically significant in both gastric carcinoma and lung carcinoma. Furthermore, when we compared MK values between patients with different tumour sizes, i.e. > 5 cm diameter, 2-5 cm and < 5 cm, there were no significant differences between the groups.
The effects of surgical removal of tumours on serum MK values were examined in five patients with hepatocellular carcinoma. In four cases, significant decrease of the values was found after tumour removal (Figure 4) .
Finally, to determine whether serum MK level was affected by inflammation, we determined serum levels of both CRP and MK of 80 outpatients with inflammation (CRP value > 0.1 mg dl -1 ) or without inflammation. However, as shown in Figure 5 , there was no or weak correlation between these two factors (P = 0.0762, correlation coefficient 0.331). Also using the same specimens, we determined leukocyte counts and found no correlation with MK serum levels (P = 0.5697, correlation coefficient -0.110).
DISCUSSION
We developed a new procedure for EIA of human MK using rabbit and chicken antibodies. Chicken and mouse MKs show 73% identity, whereas mouse and human MK show 87% identity (Raulais et al, 1991) . This sequence divergence between mammals and birds suggests that chickens immunized with human MK could produce antibodies that recognize more epitopes, including epitopes different from those recognized by the rabbit. Indeed, a combination of chicken and rabbit anti-human MK antibodies exhibited a much higher sensitivity in the detection of human MK than rabbit antibodies alone; the major epitopes recognized by chicken antibodies are probably different from those recognized by rabbit antibodies. In EIA for MK reported previously (Muramatsu et al, 1996) , we employed rabbit anti-MK antibodies and their biotinylated forms as well as avidin-β-galactosidase and a fluorogenic substrate, 4-methylumbelliferyl-β-D-galactoside. As compared to the previous method, the present EIA was advantageous in that it uses an ordinary colourimetric detection system that is more convenient for clinical use.
Using this procedure, we analysed sera from a large number of patients and found that serum MK levels were elevated in most of the cancer patients examined (87%). The ratio of patients with increased serum MK levels to total cancer patients examined agreed with that of patients with increased MK expression in tumour tissues reported previously (Tsutsui et al, 1993; Garver et al, 1994; Aridome et al, 1995; Nakagawara et al, 1995; O'Brien et al, 1996; Mishima et al, 1997; Song et al, 1997; Ye et al, 1999) . Thus, MK expressed in carcinomatous tissues is probably secreted into the bloodstream, leading to an increase in serum MK level in cancer patients. It is notable that the increased expression of MK in carcinomatous tissues and the elevated serum MK levels in cancer patients did not show specification for a particular tissue. This is reminiscent of the case of p53 mutations in human carcinomas, suggesting the biological importance of MK in carcinogenesis. The role of MK in carcinogenesis and/or tumour progression, as indicated by its transforming and angiogenic (Choudhuri et al, 1997) activities, is consistent with this assumption.
Recently, MK has been shown to have anti-apoptotic activity to embryonic neurons (Michikawa et al, 1993 , Owada et al 1999 and to Wilms' tumour cells (Qi et al, 2000) . MK also promotes migration of various cells such as embryonic neurons (Maeda et al, 1999) , neutrophils (Takada et al, 1997) and macrophages (Horiba et al, 2000) . These two activities of MK might be helpful in survival and invasion of tumour cells.
In the majority of cases, the serum MK levels decreased after surgical removal of hepatocellular carcinomas, as is expected from its nature as a tumour marker. Future study is required to know whether the value decreases in all types of tumours. The serum MK values were not significantly dependent on stages and on tumour sizes. The present study also revealed that MK values are not significantly correlated with markers of inflammation, namely CRP values and leukocyte counts. In non-malignant hepatic diseases, 14.5% of patients showed elevated serum MK values (more than 0.5 ng ml -1 ) . Although the frequency 
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Relation between C-reactive protein (CRP) and MK. Serum levels of C-reactive protein and MK were examined in 80 patients with or without inflammation. There was no or weak correlation between these two factors of elevated cases is much less as compared to be patients with carcinomas, it should be kept in mind that in certain restricted cases of non-malignant diseases, serum MK values might become elevated.
We previously found that MK expression was increased in the pre-cancerous tissue at adenoma stages of human colorectal carcinogenesis (Ye et al, 1999) . MK was also detected in latent prostate cancers and prostatic intra-epithelial neoplasia (Konishi et al, 1999) . These findings imply that MK may be useful in detecting certain carcinomas at early stages. Indeed, in the cases of gastric carcinoma and lung carcinoma, elevated serum MK level was found even at stage I. It is of significant interest whether determination of serum MK could serve as a marker in detection of these carcinomas at the early stages.
